However, currently, there is a lack of direct treatment targeting renal fibrosis, except for the prevention of acute kidney disease transitioning to CKD or delaying CKD progression using angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs), as well as mineralocorticoid receptor blockers (Klinkhammer and Boor, 2023). Here, NR3C2 is linked to chronic kidney disease.